UNSPSC 51241123: Amlexanox

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BRL1C2459K, chemically known as 5h-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid, 2-amino-7-(1-methylethyl)-5-oxo- but generally known as amlexanox, which bears US NIH Compound Identifier 2161. European Medicines Agency schedules Amlexanox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05465MIG.

UNSPSC 51241123 Amlexanox (Commodity) represents pharmaceutical products supplied through cooperative purchasing arrangements to state and local government healthcare facilities. State and local governments use this code to procure specific pharmaceutical active ingredients and finished dosage forms—in this case, amlexanox oral treatments—typically as part of broader multi-source generic drug programs that leverage authorized pharmaceutical wholesalers and centralized procurement systems. The code encompasses both the raw pharmaceutical supply chain (manufacturing, cGMP compliance, Drug Supply Chain Security Act requirements) and the administrative infrastructure required to integrate products into state healthcare networks, including electronic data interchange capabilities, chargeback systems with wholesalers, and detailed product identification through NDC codes and SKUs.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted the most relevant recent opportunity on January 20, 2026—an RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline. MMCAP represents a multi-state cooperative purchasing vehicle serving state and local government facilities across participating jurisdictions including Minnesota and Oregon. The solicitation requires vendors to supply products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), maintain cGMP certification and DSCSA compliance, hold $5 million in commercial general liability insurance, and accept performance penalties ranging from $200 to $1,500 per violation. The contract structure supports two-year initial terms for new vendors and dual or multi-awards based on therapeutic fit and member-specific needs; no specific award ceiling or budget range is disclosed in the RFP.